Recombinant prourokinase

Middle Cerebral Artery Occlusion and the PROACT Trial The safety and efficacy of lAT in the anterior circulation have been evaluated in two randomized, multicenter, placebo-controlled trials. In the Prolyse in Acute Cerebral Thromboembolism (PROACT) 1 and 11 trials, patients with proximal MCA (Ml or M2 segment) occlusions within 6 hours of symptom onset were treated with recombinant prourokinase (r-pro-UK) or placebo. ... 

Recombinant prourokinase, as the name suggests, is produced by recombinant DNA technology on binding to fibrin it converts to urokinase. The t) is 7 min. 

Recombinant prourokinase and alteplase are termed fibrin-selective, for they bind strongly to fibrin, and are capable of dissolving aging or lysis-resistant thrombi better than nonfibrin-selective agents. These drugs are less likely to produce a coagulation disturbance in the plasma, i.e. they are selective for thrombi. 

Japan pro-urokinase antithrombotic Thrombolyse Tomieze Recombinant human prourokinase, clone pA3/pD2/pFl, glycosylated Thrombosis... 

Since the human urokinase gene has now been cloned and expressed in E. coli, the prourokinase enzyme has been produced by recombinant DNA technology. Here, too, the proenzyme binds to fibrin, where, on hydrolytic action, it may exhibit good clot selectivity. The drug is investigational. 

Thrombosis is one of the most common and devastating diseases. Fibrinolytic enzymes are effectively in treating thrombosis. A variety of fibrinolytic enzymes, such as UK, streptokinase (SK), recombinant tissue-type plasminogen activator (rt-PA), staphylokinase (SAK) and recombinant prourokinase (pro-UK), have been studied as thrombolytic agents [67,68]. In general, these agents are administered via intravenous injection, and their limitations include fast clearance, lack of resistance to re-occlusion, bleeding complications and other adverse effects [67]. 

---